Oculis (NASDAQ:OCS) Trading Up 7% – Here’s Why

Shares of Oculis Holding AG (NASDAQ:OCS) shot up 7% during mid-day trading on Friday . The company traded as high as $21.03 and last traded at $21.07. 109,086 shares were traded during trading, an increase of 101% from the average session volume of 54,215 shares. The stock had previously closed at $19.70.

Analyst Upgrades and Downgrades

OCS has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Oculis in a research note on Tuesday, November 11th. Lifesci Capital assumed coverage on Oculis in a research report on Wednesday. They issued an “outperform” rating and a $55.00 price target for the company. Bank of America dropped their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. HC Wainwright boosted their price objective on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.33.

Oculis Stock Up 8.1%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The company has a fifty day simple moving average of $19.69 and a two-hundred day simple moving average of $18.74. The firm has a market capitalization of $1.11 billion, a PE ratio of -8.44 and a beta of 0.32.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. Analysts forecast that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Pivotal bioVenture Partners Investment Advisor LLC lifted its stake in shares of Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock worth $43,784,000 after buying an additional 563,078 shares during the period. Aberdeen Group plc increased its position in shares of Oculis by 24.1% in the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock valued at $23,847,000 after buying an additional 243,695 shares in the last quarter. SR One Capital Management LP acquired a new position in shares of Oculis during the 1st quarter worth approximately $6,137,000. Alyeska Investment Group L.P. acquired a new position in shares of Oculis during the first quarter valued at approximately $2,499,000. Finally, Compagnie Lombard Odier SCmA boosted its position in Oculis by 11.5% during the second quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.